Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Icecure Medical (ICCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ICCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.01
1 Year Target Price $3.01
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.59% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.92M USD | Price to earnings Ratio - | 1Y Target Price 3.01 |
Price to earnings Ratio - | 1Y Target Price 3.01 | ||
Volume (30-day avg) 3 | Beta 2.59 | 52 Weeks Range 0.48 - 1.66 | Updated Date 07/4/2025 |
52 Weeks Range 0.48 - 1.66 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -504.41% |
Management Effectiveness
Return on Assets (TTM) -72.28% | Return on Equity (TTM) -173.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 56262621 | Price to Sales(TTM) 18.92 |
Enterprise Value 56262621 | Price to Sales(TTM) 18.92 | ||
Enterprise Value to Revenue 17.19 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 58694400 | Shares Floating 30741892 |
Shares Outstanding 58694400 | Shares Floating 30741892 | ||
Percent Insiders 47.55 | Percent Institutions 0.22 |
Upturn AI SWOT
Icecure Medical
Company Overview
History and Background
IceCure Medical Ltd. was founded in 2006 and is an Israeli medical device company focused on developing and commercializing minimally invasive cryoablation technology for the treatment of tumors. It has evolved from initial research and development to clinical trials and commercial product launches.
Core Business Areas
- Cryoablation Systems: Development, manufacturing, and marketing of cryoablation systems, primarily the ProSense system, for tumor ablation.
- Single-Use Consumables: Sale of single-use cryoprobes and related consumables used with the ProSense system.
Leadership and Structure
The leadership team typically includes a CEO, CFO, and heads of research & development, operations, and sales & marketing. The organizational structure is typical of a medical device company, with departments focused on research, manufacturing, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- ProSense System: The ProSense system is IceCure's primary product, used for cryoablation of benign and malignant tumors, particularly in breast, kidney, and lung. Specific market share data is challenging to obtain and highly variable by indication. Competitors include Medtronic (MDT) and Boston Scientific (BSX) in the broader ablation market. Revenue figures are usually detailed in annual reports.
Market Dynamics
Industry Overview
The medical device industry is highly competitive and innovative, with increasing demand for minimally invasive procedures. The cryoablation market is growing, driven by the benefits of reduced recovery time and fewer complications compared to traditional surgery.
Positioning
IceCure Medical is positioned as a specialist in cryoablation technology, focusing on specific tumor types and offering a minimally invasive alternative to surgery. Their competitive advantage lies in the simplicity and effectiveness of the ProSense system.
Total Addressable Market (TAM)
The total addressable market for cryoablation is estimated to be in the hundreds of millions of dollars annually and is expanding. IceCure is positioned to capture a portion of this TAM through continued commercialization efforts and expansion into new indications.
Upturn SWOT Analysis
Strengths
- Minimally invasive technology
- Effective tumor ablation
- Established regulatory approvals
- Targeted approach in specific tumor types
Weaknesses
- Limited financial resources
- Small commercial team
- Reliance on a single primary product
- Requires more clinical trial validation in additional indications
Opportunities
- Expansion into new tumor types and indications
- Partnerships with larger medical device companies
- Increasing adoption of minimally invasive procedures
- Geographic expansion into new markets
Threats
- Competition from established medical device companies
- Technological advancements in alternative ablation techniques
- Regulatory hurdles and changes in reimbursement policies
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- BSX
- CRYO
Competitive Landscape
IceCure Medical faces competition from larger, established medical device companies with broader product portfolios. IceCure's advantage lies in its specialized cryoablation technology, while its disadvantage is its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing revenue as the ProSense system gains adoption. However, growth is variable and dependent on regulatory approvals and market penetration.
Future Projections: Future growth projections depend on successful commercialization efforts, expansion into new indications, and potential partnerships. Analyst estimates may vary.
Recent Initiatives: Recent initiatives include pursuing regulatory approvals for new indications, expanding the commercial team, and conducting clinical trials to support broader adoption of the ProSense system.
Summary
IceCure Medical is a small medical device company focused on cryoablation technology that has developed an effective product. IceCure has regulatory approvals and is expanding its commercial presence. Its small size and limited resources are weaknesses, and it needs to be mindful of its larger competitors and regulatory changes. Continued clinical validation and market adoption are important to the future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- IceCure Medical's website
- SEC filings (10-K, 10-Q)
- Press releases
- Analyst reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market share data is approximate and may vary. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Icecure Medical
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-08-26 | CEO & Director Mr. Eyal Shamir | ||
Sector Healthcare | Industry Medical Devices | Full time employees 64 | Website https://www.icecure-medical.com |
Full time employees 64 | Website https://www.icecure-medical.com | ||
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.